Atara Biotherapeutics, Inc. 8-K

What Happened Atara Biotherapeutics (ATRA) filed an 8-K (Item 5.02) announcing that Chief Accounting Officer Yanina Grant-Huerta’s employment will end effective July 17, 2026. The company’s board appointed Kevin G. Sarney as interim chief financial officer and principal financial and accounting officer effective June 26, 2026. Mr. Sarney will provide services through a consulting agreement between Atara and Charles River CFO, Inc. (CRCFO).

Key Details

• Date of CAO departure: July 17, 2026 (Yanina Grant-Huerta).
• Interim CFO start date: June 26, 2026 (Kevin G. Sarney).
• Compensation/arrangement: Mr. Sarney is provided via a consulting agreement with CRCFO; Atara pays CRCFO an agreed hourly rate and Mr. Sarney will not receive direct compensation from Atara.
• Consulting agreement terms: terminable by either party with 30 days’ written notice.
• Background on interim CFO: age 61, >25 years in finance/accounting for life sciences, CRCFO consultant since Jan 2021, former auditor at PwC, CPA (Massachusetts), degrees: B.S. Management (Univ. of Hartford), M.S. Accounting (Suffolk Univ.), MBA Finance (Boston Univ.).
• Corporate governance notes: Mr. Sarney will sign Atara’s standard indemnification agreement; no related person transactions or family relationships were reported.

Why It Matters This 8-K signals a near-term leadership change in Atara’s finance and accounting function. Appointing an experienced interim CFO via a consulting firm is intended to provide continuity for financial reporting and controls while the company transitions leadership. Investors should note the arrangement is temporary, paid through CRCFO (hourly fees), and can be ended on 30 days’ notice — factors that may affect ongoing finance operations but do not in themselves disclose any changes to financial results.